Medicxi Ventures, formerly Index Ventures Life Sciences, has officially launched closing its first fund, at €210m ($250m).
Backed, among others, by existing investors GlaxoSmithKline (GSK) and Johnson & Johnson Innovation – JJDC, Inc. (JJDC), AMedicxi Ventures 1 (MV1) will focus on making early-stage life sciences investments in Europe.
Based in London, Geneva and Jersey, Medicxi Ventures comprises all of the existing life sciences portfolio companies, funds and team from Index Ventures.
The team, led by General Partners Francesco De Rubertis (who joined Index in 1997), David Grainger (who joined Index in 2012), Kevin Johnson (who has been working with Index since 2003) and Michèle Ollier (who joined Index in 2006), has been investing in life sciences for over 20 years and has backed successful companies, including Genmab (Nasdaq Copenhagen: GEN), PanGenetics (sold to AbbVie), Molecular Partners (SWX: MOLN), XO1 (sold to Janssen) Egalet (Nasdaq: EGLT), Minerva Neurosciences (Nasdaq: NERV) and Versartis (NASDAQ: VSAR).
The Scientific Advisory Board of the new fund will include some of the top R&D and business development executives from the two pharmaceutical companies as well as Medicxi-appointed executives.